Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Doxorubicin + Pembrolizumab
Indication/Tumor Type sarcoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive sarcoma predicted - sensitive Doxorubicin + Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) and Adriamycin (doxorubicin) combination treatment resulted in a greater overall response rate (63.6% vs 22.2%, p=0.048) in patients with metastatic or unresectable anthracycline-naive soft-tissue sarcomas with a CD274 (PD-L1) H-score >=5% compared to those with a H-score less than 5% (PMID: 34475102; NCT03056001). 34475102
PubMed Id Reference Title Details
(34475102) Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma. Full reference...